EX-597 (former developmental code names URB-597, KDS-4103, and ORG-231295) is a fatty acid amide hydrolase inhibitor (FAAH inhibitor) [1] which is under development for the …

URB597 is a synthetic enzyme inhibitor developed in the last 5 years. It is the current inhibitor of choice to define fatty acid amide hydrolase (FAAH) activity, the enzyme thought to be primarily …

Aug 10, 2023 · Our results showed that URB597 dose-dependently improved neurological function and reduced brain infarct volume and brain edema 24 h after brain ischemia. The …

In the present article, we review the pharmacological properties of KDS-4103 (URB597), a highly potent and selective inhibitor of the enzyme fatty-acid amide hydrolase (FAAH), which …

Oral administration of URB597 (1–50 mg/kg, once daily) for 4 days produced a dose-dependent reduction in nocifensive responses to thermal and mechanical stimuli, which was prevented by …

URB 597 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor (IC 50 values are 3 and 5 nM in human liver and rat brain, respectively). Exhibits no significant inhibitory activity …

Oral administration of URB597 (1-50 mg/kg, once daily) for 4 days produced a dose-dependent reduction in nocifensive responses to thermal and mechanical stimuli, which was prevented by …

URB597 is a member of biphenyls. ChEBI. URB-597 is a small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication. Open Targets. 1 Structures. 1.1 2D …

URB597 is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme that hydrolyzes anandamide (AEA; Item No. 90050) and other simple esters and amides with long …

URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50 s of approximately 5 nM in rat brain membranes, 0.5 nM in intact …